Trial
NCT01133990
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eisai Inc.
Collaborators
Quintiles, Inc.
Condition
Colorectal Cancer
Intervention
FOLFIRI
Why stopped
The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not tolerable, hence no efficacy analysis was conducted.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-07